BioChange

Company Overview

Snapshot

Founded in June 2016 by Ishay Attar, BioChange operates with 11–50 employees. The company has secured $3.05 million across three funding rounds from two investors. In September 2022, BioChange announced that its foam technology for reversing receding gums was set for human use after successful trials in dogs.

Business overview

BioChange specializes in tissue regeneration technology, developing CellFoam, an injectable scaffold designed to stimulate tissue repair and remodeling. This product, based on natural biomaterials, mimics the healthy extracellular matrix to trigger the body's self-repair mechanisms through a minimally invasive procedure. The company operates within the Health Tech & Life Sciences sector, focusing on biomaterials and tissue engineering, and serves global markets.

Strategic signal

In September 2022, BioChange announced that its foam technology, designed to reverse receding gums, was nearing human application following successful canine trials. This development signals a significant step towards commercialization and validation of its core CellFoam technology, indicating potential for broader clinical applications and market entry in regenerative medicine.

Company Intelligence Q&A

What is BioChange's core technology?

BioChange's core technology is CellFoam, an injectable scaffold made from natural biomaterials that mimics the extracellular matrix to stimulate tissue repair and remodeling.

When was BioChange founded and by whom?

BioChange was founded in June 2016 by Ishay Attar, who also serves as Chairman and CEO.

What was a key development for BioChange in September 2022?

In September 2022, BioChange announced that its foam technology for reversing receding gums was set for human use, following successful trials conducted on dogs.

How much capital has BioChange raised?

BioChange has raised a total of $3.05 million across three funding rounds.